Last 282.40 INR
Change Today +6.75 / 2.45%
Volume 109.8K
SAPH On Other Exchanges
Symbol
Exchange
Natl India
As of 1:39 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

shasun pharmaceuticals ltd (SAPH) Snapshot

Open
276.80
Previous Close
275.65
Day High
286.10
Day Low
276.80
52 Week High
01/22/15 - 312.00
52 Week Low
03/25/14 - 67.70
Market Cap
17.0B
Average Volume 10 Days
191.8K
EPS TTM
5.34
Shares Outstanding
60.1M
EX-Date
07/30/14
P/E TM
52.8x
Dividend
1.00
Dividend Yield
0.35%
Current Stock Chart for SHASUN PHARMACEUTICALS LTD (SAPH)

Related News

No related news articles were found.

shasun pharmaceuticals ltd (SAPH) Related Businessweek News

No Related Businessweek News Found

shasun pharmaceuticals ltd (SAPH) Details

Shasun Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and enteric coating excipients. The company offers API products in the areas of pain management and musculoskeletal, central nervous system, cardiovascular, hyperphosphataemia, anti-infective, gastrointestinal, gastrointestinal, and other areas, as well as is developing API products in the areas of anti-depressant and anti-Parkinson’s. It is also engaged in the contract research and manufacturing services business, which provides chemistry and analytical services; and offers formulation development and manufacturing services for solid dosage products to pharmaceutical customers. In addition, the company is involved in biotechnology, nanotechnology, bulk substance, and generic drug development and manufacturing. It exports its products to North America, Europe, Asia, and Latin America. The company was formerly known as Shasun Chemicals and Drugs Ltd. Shasun Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Chennai, India.

Founded in 1976

shasun pharmaceuticals ltd (SAPH) Top Compensated Officers

Managing Director, Wholetime Director, Member...
Total Annual Compensation: 10.1M
Whole-Time Director and Member of Corporate S...
Total Annual Compensation: 6.5M
Wholetime Director and Member of Audit Commit...
Total Annual Compensation: 6.4M
Compensation as of Fiscal Year 2014.

shasun pharmaceuticals ltd (SAPH) Key Developments

Shasun Pharmaceuticals Ltd Announces Unaudited Consolidated and Standalone Earnings Results for the Second Quarter and Half Year Ended September 30, 2014

Shasun Pharmaceuticals Ltd. announced unaudited consolidated and standalone earnings results for the second quarter and half year ended September 30, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 2,658.8 million against INR 2,115.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 180.7 million against INR 157.7 million a year ago. Profit from ordinary activities before tax was INR 116.8 million against INR 115.8 million a year ago. Net profit was INR 116.8 million or INR 1.89 per diluted share after extraordinary items against INR 115.4 million or INR 2.05 per diluted share after extraordinary items a year ago. For the six months, on standalone basis, the company reported net sales/income from operations of INR 5,028.6 million against INR 3,771.9 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 296.3 million against INR 135.9 million a year ago. Profit from ordinary activities before tax was INR 153.4 million against INR 38.2 million a year ago. Net profit was INR 153.4 million or INR 2.55 per diluted share after extraordinary items against INR 140.5 million or INR 2.48 per diluted share after extraordinary items a year ago. EBITDA after R&D cost was INR 562.6 million against INR 397.4 million a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 3,060.3 million against INR 2,850.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 94.2 million against INR 154.4 million a year ago. Profit from ordinary activities before tax was INR 13.2 million against INR 133.8 million a year ago. Net profit was INR 2.5 million or INR 0.04 per diluted share after extraordinary items against INR 133.4 million or INR 2.36 per diluted share after extraordinary items a year ago. For the six months, on consolidated basis, the company reported net sales/income from operations of INR 6,058.0 million against INR 5,017.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 141.9 million against loss of INR 29.4 million a year ago. Loss from ordinary activities before tax was INR 36.9 million against INR 34.5 million a year ago. Net loss was INR 45.4 million or INR 0.75 per diluted share after extraordinary items against net profit of INR 67.7 million or INR 1.20 per diluted share after extraordinary items a year ago. EBITDA after R&D cost was INR 5,241.5 million, a growth of 21%.

Shasun Pharmaceuticals Ltd, Q2 2015 Earnings Call, Nov 06, 2014

Shasun Pharmaceuticals Ltd, Q2 2015 Earnings Call, Nov 06, 2014

Shasun Pharmaceuticals Ltd to Report Q2, 2015 Results on Nov 06, 2014

Shasun Pharmaceuticals Ltd announced that they will report Q2, 2015 results on Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAPH:IN 282.40 INR +6.75

SAPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dishman Pharmaceuticals & Chemicals Ltd 153.35 INR +0.20
Divi's Laboratories Ltd 1,770 INR +1.90
Jubilant Life Sciences Ltd 171.90 INR -4.05
Piramal Enterprises Ltd 836.00 INR -0.55
Ranbaxy Laboratories Ltd 706.30 INR -2.90
View Industry Companies
 

Industry Analysis

SAPH

Industry Average

Valuation SAPH Industry Range
Price/Earnings 86.9x
Price/Sales 1.3x
Price/Book 5.0x
Price/Cash Flow 23.6x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHASUN PHARMACEUTICALS LTD, please visit www.shasun.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.